Recent Updates
Recently added Catalysts
REGN

Regeneron Announces Upcoming 2016 Investor Conference Presentations

Key Takeaway: Regeneron Announces Upcoming 2016 Investor Conference Presentations

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+35%
120-day peak, hindsight
Typical move
2.6%
average across 15 past catalysts
Lead asset
VEGF Trap-Eye
Phase 1 · Diabetic Macular Edema

Full Press Release Details

TARRYTOWN, N.Y.,Sept. 1, 2016/PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) will webcast a management presentation at the following investor conferences:
• 2016 Credit Suisse Antibody Day at10:00 a.m. Eastern TimeonWednesday, September 7, 2016
• Morgan Stanley Global Healthcare Conference at11:40 a.m. Eastern TimeonMonday, September 12, 2016
• Bank of America Merrill Lynch Global Healthcare Conference at6:25 a.m. Eastern TimeonWednesday, September 14, 2016
The sessions may be accessed through the Company's web site,www.regeneron.com, on the 'Events and Presentations' page.  An archived version of the presentation will be available for 30 days.
About Regeneron Pharmaceuticals, Inc.Regeneron is a leading science-based biopharmaceutical company based inTarrytown, New Yorkthat discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. Regeneron commercializes medicines for eye diseases, high LDL-cholesterol, and a rare inflammatory condition and has product candidates in development in other areas of high unmet medical need, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases. For additional information about the Company, please visitwww.regeneron.comor follow @Regeneron on Twitter.
Investor Relations                                                         Corporate CommunicationsManisha Narasimhan, Ph.D.                                          Hala Mirza914.847.5126                                                               914.847.3422[email protected][email protected]
Last updated: Sep 1, 2016